Risk factors
GT Biopharma (GTBP) risk factors
Item 1A of every GT Biopharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors53 risks3 new4 dropped10 reworded
The company faces severe dilution, holding 25,534,173 shares and 50,532,927 warrants, alongside a Nasdaq minimum bid price compliance warning.
Filed Mar 02, 2026 - FY2024 10-K risk factors54 risks
GT Biopharma faces critical going concern doubt with only $4.0 million in cash against a $1.7 million working capital deficit. The company has a history of operating losses totaling $695 million and no product revenue. Operations depend heavily on outsourced manufacturers, third-party licenses, and a tiny team of one full-time employee plus consultants.
Filed Feb 21, 2025